ESSA Pharma Completes Acquisition by XenoTherapeutics, Expanding Biotech Horizons

ESSA Pharma Inc.'s Acquisition by XenoTherapeutics: A New Chapter Begins

On October 9, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) announced the successful completion of its acquisition by XenoTherapeutics, Inc., a notable milestone in the biotech sector. This acquisition signals a strategic move aimed at enhancing the development of innovative therapies, particularly for prostate cancer.

XenoTherapeutics, a Massachusetts-based research foundation dedicated to advancing xenotransplantation, has acquired all outstanding common shares of ESSA at a price of approximately $0.1242 per share. Additionally, shareholders will receive one contingent value right (CVR) per common share, allowing for potential payments totaling approximately $6.7 million based on specific milestones related to certain liabilities. This provides an added incentive for existing shareholders as the merger brings a new vision for both companies.

The Approval Process and Future Expectations

The path to the acquisition was paved with significant legal frameworks, including a final order issued by the Supreme Court of British Columbia on October 7, 2025. This order approved the arrangement, allowing ESSA to proceed with plans for delisting its shares from the Nasdaq Capital Market. Following the close of this acquisition, ESSA will request a filing that indicates the termination of its registration under the U.S. Securities Exchange Act of 1934 in about ten days.

The transaction was facilitated through the expertise of financial advisors. Leerink Partners LLC acted as ESSA's exclusive financial advisor for the acquisition, while Blake, Cassels & Graydon LLP and Skadden, Arps, Slate, Meagher & Flom LLP provided Canadian and U.S. legal counsel, respectively.

A New Era for ESSA Pharma

ESSA has historically concentrated on formulating proprietary therapies aimed at treating prostate cancer, and this acquisition is expected to catalyze its mission. Bringing together both companies' resources is aimed at bolstering the research and development efforts that could lead to groundbreaking findings in cancer treatment.

Insights into XenoTherapeutics

XenoTherapeutics is primarily known for its dedication to scientific research and clinical advancements in the realm of xenotransplantation. This approach is a promising field that involves the transplantation of organs and tissues between different species, and its successful development could revolutionize medical treatment options for numerous ailments.

The merger is also a strategic alignment with the growing public interest in innovative healthcare solutions. Both companies are at the forefront of utilizing cutting-edge technology and research methodologies to deliver enhanced therapeutic solutions to patients.

Looking Ahead

The acquisition opens doors for numerous opportunities as ESSA Pharma integrates with XenoTherapeutics. Industry experts foresee innovative therapeutic solutions and significant advancements in scientific research that may emerge as both organizations collaborate.

However, as with any merger, a range of risks and uncertainties lie ahead. These include potential legal challenges, organizational disruptions, and the necessary navigation of regulatory frameworks that could affect operations in the near future.

As ESSA Pharma Inc. embarks on this transformative journey with XenoTherapeutics, stakeholders and the industry await developments that could not only reshape the companies but also contribute positively to the future of healthcare. Stakeholders are reminded that due diligence and ongoing evaluations will be essential as the integrated entity seeks to realize its full potential in delivering novel cancer therapies.

For more information about ESSA Pharma, visit www.essapharma.com and for insights into XenoTherapeutics, explore www.xenotx.org.